1. Arnold SE, Trojanowski JQ (1996) Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol (Berl) 92: 217–231
2. Barone FC, White RF, Spera PA, Ellison J, Currie RW, Wang X, Feuerstein GZ (1998) Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. Stroke 29: 1937–1950; discussion 1950–1951
3. Campana WM, Misasi R, O’Brien JS (1998) Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med 1: 235–241
4. Cannon TD, Thompson PM, van Erp TGM, Toga AW, Huttunen M, Lönnqvist J, Standertsköld-Nordenstam C-GA (2001) A probabalistic Atlas of Cortical Gray Matter Changes in Monozygotic Twins Discordant for Schizophrenia. International Congress on Schizophrenia Research; Whistler, Canada
5. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179–186